Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying disease progression and prolonging the survival of people with metastatic triple-negative breast cancer (mTNBC). The biopharmaceutical company had closed ASCENT (NCT02574455) early, in April, due to the strong evidence already gathered of Trodelvy’s ability to halt disease progression in these patients. “The results of the global…
You must be logged in to read/download the full post.
The post Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows appeared first on BioNewsFeeds.